Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

U.S. FDA raises concerns over Valeant's eye drop

Published 2016-07-22, 03:36 a/m
© Reuters.  U.S. FDA raises concerns over Valeant's eye drop
BHC
-

July 22(Reuters) - Valeant Pharmaceuticals (NYSE:VRX) International VRX.TO VRX.N said on Friday U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch + Lomb facility in Florida.

The U.S. Food and Drug Administration, in a complete response letter (CRL) regarding the eye drop for a type of glaucoma, raised concerns over Current Good Manufacturing Practice at the unit.

The letter did not identify any efficacy or safety issues with the eye drop, a latanoprostene bunod ophthalmic solution.

Valeant said it intends to meet the regulators and resolve these concerns, the company said in a statement. care unit Bausch + Lomb is one of Valeant's core assets and a frachise to build on, billionaire investor and Valeant board member Bill Ackman said last week.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.